RHC – UBS rates the stock as Neutral

By Broker News | More Articles by Broker News

The UK NHS has published hospital activity data for April. UBS estimates NHS e-referrals represent around 79% of Ramsay Health Care’s UK total admissions. April volumes for Ramsay decreased -2.9% while 12-month rolling growth moderated to 4.9% from 6.5% at the end of March.

UBS believes the current admissions data combined with a tariff increase should support robust growth in NHS-derived revenue in the second half and into FY20.

However, based on increased usage of agency nursing to manage the higher caseload, UBS models a -40 basis points decline in UK earnings (EBIT) margin in the second half. Neutral rating and $68.40 target maintained.

Sector: Health Care Equipment & Services.

Target price is $68.40.Current Price is $72.54. Difference: ($4.14) – (brackets indicate current price is over target). If RHC meets the UBS target it will return approximately -6% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →